SCHEMBL16693153

SCHEMBL16693153

COc1ccc(CN2CCCc3cc(C=O)ccc32)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HPGD P15428 2/20 0.49
GAA P10253 2/20 0.49
LMNA P02545 3/20 0.47
POLB P06746 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ALDH1A3 P47895 1/20 0.45
KDM4E B2RXH2 4/20 0.45
HSD17B10 Q99714 1/20 0.42
APLNR P35414 1/20 0.42
MAPK1 P28482 2/20 0.42
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16693159 0.82 KDM4E (0.59) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL8373325 0.76 MTNR1A (0.52) ALDH1A1MEN1KMT2ALMNAHDAC1
SCHEMBL10268440 0.76 KDM4E (0.58) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL10689705 0.74 ALDH1A1 (0.66) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL1461837 0.73 ALDH1A1 (0.56) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL20869585 0.72 ALDH1A1 (0.56) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL27923217 0.72 ACHE (0.56) ALDH1A1MEN1KMT2AL3MBTL1HDAC1
SCHEMBL21031899 0.72 KDM4E (0.42) ALDH1A1MEN1KMT2AGAAPOLB
SCHEMBL7359117 0.71 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AHPGDL3MBTL1
SCHEMBL10640944 0.71 KDM4E (0.53) MAPTALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 MAPT 2871/4885ALDH1A1 3122/4885MEN1 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.